{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-043472","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2021-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.388897+00:00","generated_at":"2026-06-29T15:19:43.528611+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Arcus board member Quigley resigns; Linda Higgins appointed as Gilead designee","bullets":["Michael Quigley resigned from Arcus board effective upon appointment of Gilead's new designee, following his departure from Gilead.","Linda Higgins, SVP of Research at Gilead, appointed as Class III director; she previously led Biology at Gilead since 2010.","Higgins will not receive compensation for Arcus board service; standard indemnification agreement expected.","Changes effective August 10, 2021, under the Investor Rights Agreement with Gilead dated May 2020."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-043472","json":"https://secwatch.observer/filing/0001564590-21-043472.json","markdown":"https://secwatch.observer/filing/0001564590-21-043472.md","text":"https://secwatch.observer/filing/0001564590-21-043472.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000156459021043472/0001564590-21-043472-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000156459021043472/rcus-8k_20210810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T15:19:43.528611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ad8047f6ef","claim":"Linda Higgins was appointed as Director at Arcus Biosciences, Inc..","evidence_excerpt":"On August 10, 2021, the Board appointed Linda Higgins, Senior Vice President of Research, External Innovation at Gilead, as a Class III director to fill the vacancy left by Dr. Quigley’s resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1724521/000156459021043472/0001564590-21-043472-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e681011a3d","claim":"Michael Quigley resigned as Director at Arcus Biosciences, Inc..","evidence_excerpt":"Michael Quigley, Ph.D., resigned as a member of Arcus Biosciences, Inc.’s Board of Directors, effective upon the appointment of Gilead’s new director designee","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1724521/000156459021043472/0001564590-21-043472-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}